Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.
Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators.
Polman C, et al.
J Neurol. 2008 Apr;255(4):480-7. doi: 10.1007/s00415-007-0733-2. Epub 2007 Nov 15.
J Neurol. 2008.
PMID: 18004635
Clinical Trial.